<DOC>
	<DOC>NCT01292161</DOC>
	<brief_summary>The purpose of this study is to determine the effects of silymarin on outcomes of patients with hepatitis C.</brief_summary>
	<brief_title>Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>Silymarin has been claimed to have a beneficial effect in various types of liver injury, including alcoholic liver disease, drug and toxin induced hepatotoxicity, and acute and chronic viral hepatitis.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>confirmed chronic hepatitis C (HCV Ab (+), HCV RNA (with PCR) (+)) normal or increased liver enzymes (ALT and AST) not using interferon or ribavirin due to patient sensitivity or not consenting. The pregnant patients patients with side effect which confirmed with rechallenge test</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Silymarin</keyword>
	<keyword>Quality of life</keyword>
</DOC>